Navigation Links
Foundation Venture Capital Group Commits Second Round of Funding to Actinobac Biomed
Date:2/21/2013

NEW BRUNSWICK, N.J., Feb. 21, 2013 /PRNewswire-USNewswire/ -- Actinobac Biomed, Inc., has received a commitment for a second investment of $100,000 from Foundation Venture Capital Group (FVCG) to  study the efficacy of the company's lead product, Leukothera®, in  the treatment of  veterinary white blood cell diseases , announced Dr. George F. Heinrich , vice chair and CEO of FVCG.

FVCG had originally invested $500,000 when Actinobac was first established in 2009 to develop pharmaceutical agents for the treatment of hematologic malignancies (leukemias & lymphomas), latent infections (HIV/AIDS & tuberculosis) and autoimmune diseases (rheumatoid arthritis, multiple sclerosis, Crohn's disease, type 1 diabetes, Lupus & psoriasis).

Leukothera® is a bacterial toxin that specifically targets and depletes disease related white blood cells (WBC). In laboratory studies to date, malignant and proinflammatory white blood cells have been determined to be more sensitive to Leukothera® than normal white blood cells. Animal studies carried out by Actinobac have shown Leukothera™ to possess significant therapeutic activity.

"We are contracting with Texas A&M Veterinary School to examine the use of Leukothera® for dogs suffering with white blood cell diseases," explained company founder Dr. Scott Kachlany.  "Because of biological similarities, the data we obtain from these new studies will be applicable to dogs and support drug development for human applications also."

The latest $100,000 investment will fund proof of concept studies. According to Dr. Kachlany, early results indicate that Actinobac's drug candidate works very well in healthy dogs, using lower doses than previously expected.

"We are excited about Dr. Kachlany's results to date," explained James M. Golubieski , president of Foundation Venture Capital Group, "and are hopeful that Actinobac's work will provide a viable treatment in the not too distant future to increase survival rates for these white blood cell diseases."

Dr. Kachlany, also an associate professor of oral biology, microbiology and molecular genetics at UMDNJ-New Jersey Dental School, discovered the potential therapeutic uses of Leukothera®  during the course of his research at the dental school.

"Our goal is to demonstrate that Leukothera® prolongs life and treats disease, in dogs and in humans," he explained.

For more information contact James M. Golubieski , president of Foundation Venture Capital Group, at jgolubieski@njhf.org  or visit www.actinobac.com and  www.foundationventure.com.

About Foundation Venture Capital Group

Foundation Venture Capital Group, an affiliate of New Jersey Health Foundation, invests in commercially viable new start-up companies developing technology by faculty at or affiliated with the University of Medicine and Dentistry of New Jersey.  In addition to Actinobac, FVCG portfolio companies currently include: 

  • Affineti Biologics, Inc.,  advancing research in the development of therapeutic and diagnostic products based on new discoveries in oral biology and dental medicine;
  • CellXplore, Inc., engaged in the development of biomarker-based in vitro diagnostic assays for cancer;
  • Celvive, Inc., working to develop technology to treat patients with chronic spinal cord injuries with their own adult stem cells;
  • Durin Technologies, working to develop a blood test to diagnose Alzheimer's, Parkinson's and other neurodegenerative diseases;
  • GeneAssess, Inc.,  a company developing a diagnostic tool for more accurate breast cancer staging;
  • Longevica Pharmaceuticals, Inc., developing a chemoprotective agent that may keep normal cells healthy during cancer treatments (FVCG's equity interest in Longevica was sold to Rostock International, LTD, a subsidiary of a Moscow (Russia) based global investment firm);
  • MentiNova, Inc., working to reduce side effects of L-Dopa Induced Dyskinesia
  • Snowdon Pharmaceuticals, Inc., a drug discovery company focused on several major therapeutic areas.


'/>"/>
SOURCE New Jersey Health Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Simbionix firma un acuerdo con la Laparoscopic Surgical Skills Foundation (LSS)
2. Simbionix Signs an Agreement with the Laparoscopic Surgical Skills Foundation (LSS)
3. The Michael J. Fox Foundation Launches New Funding Opportunities for Parkinsons Research
4. National Patient Advocate Foundation Supports 340B Drug Discount Program Review Identifying Risks to Underinsured Patients
5. Metabolic Solutions Development Company Awarded Funding by The Michael J. Fox Foundation
6. Se crea en Taiwán la Tang Prize Foundation
7. Tang Prize Foundation Established in Taiwan: Academia Sinica to be Responsible for the Nomination and Selection of the International Awards in Taiwan
8. Foundation Venture Capital Group Invests In Start-Up Working to Reduce Side Effects of Parkinsons Treatment
9. Asthma and Allergy Foundation of America Challenges Patients and Caregivers to Get Smart About Asthma
10. New Jersey Health Foundation Awards First Two Innovation Stage Funding Grants
11. UCB, Inc. and Arthritis Foundation Partner to Celebrate the "Everyday Victories" of the Rheumatoid Arthritis Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... ORLANDO, Fla. , Oct. 2, 2017  AllianceRx ... services company formed by Walgreens and pharmacy benefit manager ... of its new brand, which included the unveiling of ... Fla. , as well as at a few ... introduces the new brand to patients, some of whom ...
(Date:9/27/2017)... their devotion to personalized service, SMP Pharmacy Solutions announces their ... South Florida Business Journal,s 50 Fastest-Growing Companies, and listed for ... specialty pharmacy has found its niche.  To that end, the ... by SFBJ as the 2017 Power Leader in Health Care. ... award in October, Bardisa said of the three achievements, "It,s ...
(Date:9/22/2017)... Md. , Sept. 22, 2017  As the ... Republican Senators Bill Cassidy (R-LA) and ... Information notes that the medical device industry is in ... medical device tax, the 2.3% excise tax on medical ... But they also want covered patients, increased visits and ...
Breaking Medicine Technology:
(Date:10/13/2017)... IL (PRWEB) , ... October 13, 2017 , ... ... which established the certification process to promote standards of excellence for the field ... Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at the ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate ... primary prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton ... staged a mock evacuation of the facility as part of a disaster drill on ... Echo Hose EMS and Shelton City Emergency Manager, as well as the Connecticut ...
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids this ... by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited about ... ages; it is a non-competitive, non-timed event, which is all about having fun and ...
Breaking Medicine News(10 mins):